Cardio Diagnostics Holdings, Inc. Files 8-K

TL;DR

CDIO filed an 8-K on Nov 15th covering shareholder votes and financials.

AI Summary

Cardio Diagnostics Holdings, Inc. filed an 8-K on November 15, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly known as Mana Capital Acquisition Corp., is incorporated in Delaware and operates in the in vitro & in vivo diagnostic substances sector.

Why It Matters

This filing provides updates on corporate actions and financial reporting for Cardio Diagnostics, which is crucial for investors to understand the company's current status and governance.

Risk Assessment

Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

• Cardio Diagnostics Holdings, Inc. (company) — Registrant
• Mana Capital Acquisition Corp. (company) — Former company name
• November 15, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 CDIO The Nasdaq Stock Market LLC

Filing Documents

• cdio_8k.htm (8-K) — 40KB
• 0001079973-24-001569.txt ( ) — 258KB
• cdio-20241115.xsd (EX-101.SCH) — 4KB
• cdio-20241115_def.xml (EX-101.DEF) — 26KB
• cdio-20241115_lab.xml (EX-101.LAB) — 36KB
• cdio-20241115_pre.xml (EX-101.PRE) — 25KB
• cdio_8k_htm.xml (XML) — 6KB

07

Item 5.07. Submission of Matters to a Vote of Security Holders. On November 15, 2024 Cardio Diagnostics Holdings, Inc., a Delaware corporation (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). Of the Company's 25,905,656 shares of common stock issued and outstanding and eligible to vote as of the record date of September 24, 2024, a total of 14,116,148 shares, or approximately 55.51% of the eligible shares, was in attendance or represented by proxy. The Company's stockholders voted on four proposals as set forth below. Each of the proposals is described in further detail in the Company's definitive proxy statement, which was filed with the Securities and Exchange Commission on October 4, 2024. The final voting results, including the number of votes cast for, against, or withholding authority, and the number of abstentions and any broker non-votes, with respect to each matter voted upon are set forth below, as reported by the Company's independent inspector of election. Proposal 1: Election of Directors (the "Election of Directors Proposal") The Company's stockholders elected seven directors to serve for the ensuing year and until their successors are elected and qualified, or until their earlier death, resignation or removal. The Company elects its directors on a plurality vote basis. The votes regarding the election of directors were as follows: Nominee For Authority Withheld Broker Non-Votes Meeshanthini Dogan, Ph.D. 7,267,292 834,310 6,014,546 Robert Philibert, M.D., Ph.D. 7,266,486 835,116 6,014,546 Paul F. Burton, J.D., MBA 7,466,218 635,384 6,014,546 Warren Hosseinion, M.D. 6,215,891 1,885,711 6,014,546 James Intrater 7,269,764 831,838 6,014,546 Wendy J. Betts 7,314,250 787,352 6,014,546 Peter K. Fung, M.D. 7,308,868 792,734 6,014,546 Proposal 2: Approval of an amendment to the Company's Third Amended and Restated Certificate of Incorporation to effect a revers

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 18, 2024 CARDIO DIAGNOSTICS HOLDINGS INC. By: /s/ Elisa Luqman Elisa Luqman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR